angiotensin ii has been researched along with catalpol in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 2 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, CX; Dong, Z | 1 |
| Chen, W; Cong, C; Hu, Y; Tao, L; Wang, Y; Yuan, X | 1 |
| Hao, RJ; Lu, YW; Xia, Y; Yu, GR | 1 |
3 other study(ies) available for angiotensin ii and catalpol
| Article | Year |
|---|---|
Effect of catalpol on diabetic nephropathy in rats.
Topics: Angiotensin II; Animals; Collagen Type IV; Connective Tissue Growth Factor; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Drugs, Chinese Herbal; Fibronectins; Iridoid Glucosides; Kidney; Male; Organ Size; Phytotherapy; Random Allocation; Rats; Rats, Sprague-Dawley; Rehmannia; RNA, Messenger; Transforming Growth Factor beta1 | 2013 |
Catalpol Alleviates Ang II-Induced Renal Injury Through NF-κB Pathway and TGF-β1/Smads Pathway.
Topics: Angiotensin II; Animals; Anti-Inflammatory Agents; Cell Line; Disease Models, Animal; Fibrosis; Humans; Inflammation Mediators; Iridoid Glucosides; Kidney; Male; Mice; Mice, Inbred C57BL; Nephritis; NF-kappa B; Rats; Signal Transduction; Smad Proteins; Transforming Growth Factor beta1 | 2022 |
Catalpol relieved angiotensin II-induced blood-brain barrier destruction via inhibiting the TLR4 pathway in brain endothelial cells.
Topics: Angiotensin II; Animals; Blood-Brain Barrier; Endothelial Cells; Lipopolysaccharides; Mice; Myeloid Differentiation Factor 88; NF-kappa B; Toll-Like Receptor 4; Tumor Necrosis Factor-alpha | 2022 |